Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yokohama City University Medical Center
• Collaborator: Novartis Pharmaceuticals
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept.

Exclusion Criteria:

• patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.